Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Immunotherapy did not improve overall survival but led to fewer side effects and better quality of life.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Half of people with worse liver function responded well to immunotherapy.
Recommendations now include multiple systemic medications in addition to surgery and local therapies.
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.
Opdivo will be used to treat hepatocellular carcinoma, which can be caused by hepatitis B or C.
More treatment options may soon become available for those with hepatocellular carcinoma, which is often diagnosed late.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.